Non-standard insulin analogues
An insulin analogue comprises a B-chain polypeptide containing at least one alteration selected from a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide. A first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate. The methylated phenylalanine may be ortho-monofluoro-phenylalanine, meta-monobromo-phenylalanine or para-monochloro-phenylalanine. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of treating a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
1. An insulin analogue comprising an insulin B-chain polypeptide containing at least one alteration selected from:
a methylated phenylalanine substitution at position B24; and
an addition of two amino acids to the carboxyl end of the B-chain polypeptide, wherein a first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate.
2. The insulin analogue of claim 1 , wherein the methylated phenylalanine is ortho-monomethyl-phenylalanine, meta-monomethyl-phenylalanine or para-monomethyl-phenylalanine.
3. The insulin analogue of claim 2 , wherein the methylated phenylalanine is ortho-monomethyl -phenylalanine.
4. The insulin analogue of claim 1 , wherein at least one of the first and second amino acids is glutamate.
5. The insulin analogue of claim 4 , wherein the first amino acid and the second amino acid are both glutamate.
6. The insulin analogue of claim 1 , wherein the insulin B-chain polypeptide comprises both a methylated phenylalanine substitution at position B24 and an addition of two amino acids to the carboxyl end of the B-chain polypeptide, wherein a first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate.
7. The insulin analogue of claim 6 , wherein the methylated phenylalanine is ortho-monomethyl -phenylalanine.
8. The insulin analogue of claim 7 , wherein at least one of the first and second amino acids is glutamate.
9. The insulin analogue of claim 8 , wherein the first amino acid and the second amino acid are both glutamate.
10. The insulin analogue of claim 9 , additionally comprising a paired substitution selected from a lysine substitution at position B28 with a proline substitution at position B29, or an aspartate substitution at position B28 with a proline substitution at position B29.
11. The insulin analogue of claim 8 , additionally comprising a paired substitution selected from a lysine substitution at position B28 with a proline substitution at position B29, or an aspartate substitution at position B28 with a proline substitution at position B29.
12. The insulin analogue of claim 1 , wherein the analogue is an analogue of a mammalian insulin.
13. The insulin analogue of claim 12 , wherein the analogue is an analogue of human insulin.
14. The insulin analogue of claim 13 , wherein the B-chain polypeptide comprises an amino acid sequence of SEQ. ID. NO. 26.
15. A method of treating diabetes in a patient in need thereof comprising administering a physiologically effective amount of an insulin analogue or a physiologically acceptable salt thereof to the patient, wherein the insulin analogue or a physiologically acceptable salt thereof contains a B-chain polypeptide incorporating at least one alteration selected from:
a methylated phenylalanine at position B24, and
an addition of two amino acids to the carboxyl end of the B-chain polypeptide, wherein a first amino acid at position B31 is selected from glutamate and aspartate, and a second amino acid at position B32 is selected from glutamate, alanine and aspartate.